Ramasamy K, Bahlis NJ, Kumar SK, Kumar A, Cranmer H, Wang B, Dabora J, Labotka R, Richardson PG, Moreau P. Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone. haematol [Internet]. 2024Aug.1 [cited 2025Dec.19];109(8):2585-93. Available from: https://haematologica.org/article/view/haematol.2023.283713